儿童神经肿瘤患者靶向下一代测序可改善诊断、识别致病性胚系突变并指导靶向治疗
本文报告31例儿童神经肿瘤患者接受510个癌症相关基因的靶向测序,25例(81%)结果影响临床管理,6例(19%)病理诊断被修正,19例(61%)发现潜在可靶向改变,并识别出多种致病性胚系突变。作者认为分子谱分析对儿童脑肿瘤诊断和治疗有显著影响,并确认其在诊断或复发时应用的可行性。
要点
- 31例儿童神经肿瘤患者中,25例(81%)的测序结果影响了临床管理。
- 6例(19%)患者经基因组谱分析后病理诊断被修正。
- 19例(61%)患者检出潜在可靶向改变,多名患者携带既往未疑及的致病性胚系突变。
核心结论
- 作者的临床经验表明,分子谱分析对儿童脑肿瘤的诊断和治疗有显著影响,并确认其在诊断或复发时应用的可行性。
研究设计与样本
- 对31例儿童神经肿瘤患者,从肿瘤和外周血中测序510个癌症相关基因,以识别胚系和体细胞突变、结构变异及拷贝数变化。
主要发现
- 31例患者的肿瘤包括11例高级别胶质瘤、8例髓母细胞瘤、6例低级别胶质瘤、1例多层菊形团胚胎性肿瘤、1例松果体母细胞瘤、1例葡萄膜神经节神经瘤、1例脉络丛癌、1例脊索瘤和1例高级别神经上皮肿瘤。
- 25例(81%)的测序结果通过以下方式影响患者管理:明确诊断、识别致病性胚系突变或检出潜在可靶向改变。
- 6例(19%)患者在基因组谱分析后病理诊断被修正,包括高级别胶质瘤改为毛细胞型星形细胞瘤、髓母细胞瘤改为松果体母细胞瘤、室管膜瘤改为高级别胶质瘤、髓母细胞瘤改为伴BCOR改变的中枢神经系统高级别神经上皮肿瘤。
- 19例(61%)患者检出潜在可靶向改变;多名患者携带致病性胚系突变,其中许多既往未被疑及。
- 另在3例中检出新的可能致病性改变:BRAF野生型多形性黄色星形细胞瘤中的框内RAF1融合、组蛋白H3野生型弥漫性脑桥胶质瘤中的失活ASXL1突变、低级别星形细胞肿瘤中MAP2K1外显子2的框内缺失。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular profiling is revolutionizing cancer diagnostics and leading to personalized therapeutic approaches. Herein we describe our clinical experience performing targeted sequencing for 31 pediatric neuro-oncology patients. METHODS: We sequenced 510 cancer-associated genes from tumor and peripheral blood to identify germline and somatic mutations, structural variants, and copy number changes. RESULTS: Genomic profiling was performed on 31 patients with tumors including 11 high-grade gliomas, 8 medulloblastomas, 6 low-grade gliomas, 1 embryonal tumor with multilayered rosettes, 1 pineoblastoma, 1 uveal ganglioneuroma, 1 choroid plexus carcinoma, 1 chordoma, and 1 high-grade neuroepithelial tumor. In 25 cases (81%), results impacted patient management by: (i) clarifying diagnosis, (ii) identifying pathogenic germline mutations, or (iii) detecting potentially targetable alterations. The pathologic diagnosis was amended after genomic profiling for 6 patients (19%), including a high-grade glioma to pilocytic astrocytoma, medulloblastoma to pineoblastoma, ependymoma to high-grade glioma, and medulloblastoma to CNS high-grade neuroepithelial tumor with BCOR alteration. Multiple patients had pathogenic germline mutations, many of which were previously unsuspected. Potentially targetable alterations were identified in 19 patients (61%). Additionally, novel likely pathogenic alterations were identified in 3 cases: an in-frame RAF1 fusion in a BRAF wild-type pleomorphic xanthoastrocytoma, an inactivating ASXL1 mutation in a histone H3 wild-type diffuse pontine glioma, and an in-frame deletion within exon 2 of MAP2K1 in a low-grade astrocytic neoplasm. CONCLUSIONS: Our experience demonstrates the significant impact of molecular profiling on diagnosis and treatment of pediatric brain tumors and confirms its feasibility for use at the time of diagnosis or recurrence.
引用
- Kline CN, Joseph NM, Grenert JP, et al. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol. 2017. PMID: 28453743. doi:10.1093/neuonc/now254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。